<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ibañez, Lorena Itatí</style></author><author><style face="normal" font="default" size="100%">Roose, Kenny</style></author><author><style face="normal" font="default" size="100%">De Filette, Marina</style></author><author><style face="normal" font="default" size="100%">Schotsaert, Michael</style></author><author><style face="normal" font="default" size="100%">De Sloovere, Jessica</style></author><author><style face="normal" font="default" size="100%">S. Roels</style></author><author><style face="normal" font="default" size="100%">Pollard, Charlotte</style></author><author><style face="normal" font="default" size="100%">Schepens, Bert</style></author><author><style face="normal" font="default" size="100%">Grooten, Johan</style></author><author><style face="normal" font="default" size="100%">Fiers, Walter</style></author><author><style face="normal" font="default" size="100%">Saelens, Xavier</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">M2e-displaying virus-like particles with associated RNA promote T helper 1 type adaptive immunity against influenza A.</style></title><secondary-title><style face="normal" font="default" size="100%">PLoS One</style></secondary-title><alt-title><style face="normal" font="default" size="100%">PLoS ONE</style></alt-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Adaptive Immunity</style></keyword><keyword><style  face="normal" font="default" size="100%">Adaptor Proteins, Vesicular Transport</style></keyword><keyword><style  face="normal" font="default" size="100%">Animals</style></keyword><keyword><style  face="normal" font="default" size="100%">Female</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">Immunity, Cellular</style></keyword><keyword><style  face="normal" font="default" size="100%">Influenza A Virus, H3N2 Subtype</style></keyword><keyword><style  face="normal" font="default" size="100%">Influenza Vaccines</style></keyword><keyword><style  face="normal" font="default" size="100%">Influenza, Human</style></keyword><keyword><style  face="normal" font="default" size="100%">Lung</style></keyword><keyword><style  face="normal" font="default" size="100%">mice</style></keyword><keyword><style  face="normal" font="default" size="100%">Myeloid Differentiation Factor 88</style></keyword><keyword><style  face="normal" font="default" size="100%">Orthomyxoviridae Infections</style></keyword><keyword><style  face="normal" font="default" size="100%">Rna</style></keyword><keyword><style  face="normal" font="default" size="100%">Signal Transduction</style></keyword><keyword><style  face="normal" font="default" size="100%">Th1 Cells</style></keyword><keyword><style  face="normal" font="default" size="100%">Vaccination</style></keyword><keyword><style  face="normal" font="default" size="100%">Vaccines, Virus-Like Particle</style></keyword><keyword><style  face="normal" font="default" size="100%">Viral Load</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2013</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">8</style></volume><pages><style face="normal" font="default" size="100%">e59081</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;The ectodomain of influenza A matrix protein 2 (M2e) is a candidate for a universal influenza A vaccine. We used recombinant Hepatitis B core antigen to produce virus-like particles presenting M2e (M2e-VLPs). We produced the VLPs with and without entrapped nucleic acids and compared their immunogenicity and protective efficacy. Immunization of BALB/c mice with M2e-VLPs containing nucleic acids induced a stronger, Th1-biased antibody response compared to particles lacking nucleic acids. The former also induced a stronger M2e-specific CD4(+) T cell response, as determined by ELISPOT. Mice vaccinated with alum-adjuvanted M2e-VLPs containing the nucleic acid-binding domain were better protected against influenza A virus challenge than mice vaccinated with similar particles lacking this domain, as deduced from the loss in body weight following challenge with X47 (H3N2) or PR/8 virus. Challenge of mice that had been immunized with M2e-VLPs with or without nucleic acids displayed significantly lower mortality, morbidity and lung virus titers than control-immunized groups. We conclude that nucleic acids present in M2e-VLPs correlate with improved immune protection.&lt;/p&gt;</style></abstract><issue><style face="normal" font="default" size="100%">3</style></issue><custom1><style face="normal" font="default" size="100%">http://www.ncbi.nlm.nih.gov/pubmed/23527091?dopt=Abstract</style></custom1></record></records></xml>